Related Experiment Video

Updated: May 3, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K

Periorbital necrobiotic xanthogranuloma treated successfully with novel multiple myeloma therapy

Sofia Ghani1, Omar Al Ustwani1, Bilal Khalid1

  • 1Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.

Clinical Advances in Hematology & Oncology : H&O
|February 13, 2014
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

12.5K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

5.7K

Related Experiment Videos

Last Updated: May 3, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

12.5K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

5.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K

Articles linked to this work by shared authors, journal, and citation graph.

Crystallized colony-stimulating factor-1 receptor inhibitor protects immunoisolated allo but not xeno transplants in primates.

Science translational medicine·2026

Antibiotic Sensitivity Pattern of Common Microorganisms Isolated From Surgical Site Infections (SSIs) After Abdominal Surgeries at Ayub Teaching Hospital in Abbottabad, Pakistan.

Cureus·2026

Gamma Irradiation of Poly(lactide-co-glycolide) Scaffolds Reduces the Mechanical Stability and Function of Islet Grafts in Diabetic Nonhuman Primates.

Biotechnology and bioengineering·2025

Breast density classification using frequency-based features in microwave imaging.

Scientific reports·2025

Trial Frequency Outweighs Trial Duration in Associative Learning: Generality and Boundary Conditions.

Quarterly journal of experimental psychology (2006)·2025

Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Artificial intelligence in prostate cancer diagnosis and management: state-of-the-art approaches and emerging innovations.

Clinical advances in hematology & oncology : H&O·2026

Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.

Clinical advances in hematology & oncology : H&O·2026

Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer.

Clinical advances in hematology & oncology : H&O·2026

Treatment with CFTR modulators and subsequent remission of AA amyloidosis.

Clinical kidney journal·2026

Correction: Targeting oxidized phosphatidylcholines in SOD1-associated ALS: therapeutic potential of PC-OxPL-VecTab®.

Frontiers in neuroscience·2026

Comparison of Peg-INF plus TDF versus TDF Monotherapy in Indeterminate-phase Chronic Hepatitis B Patients with High HBsAg levels, HBeAg-negative status, and Normal ALT Levels.

Journal of clinical and translational hepatology·2026

Novel and Emerging Therapies for Childhood-Onset Movement Disorders.

Movement disorders : official journal of the Movement Disorder Society·2026

Implementation of soluble CD38 in blood crossmatching for patients on anti-CD38 therapy: A single-center experience.

Transfusion·2026

FAP+ pericyte-like cells promote monocyte differentiation into tumor-associated macrophages in glioblastoma.

Experimental & molecular medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us